Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 12, 2015, Pages 2429-2437

  Mutters, N T ^a   Zimmermann, S ^a   Kaase, M ^b   Mischnik, A ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEMASE; CEFTAZIDIME; ERTAPENEM; IMIPENEM; MECILLINAM; MEROPENEM; TEMOCILLIN; BACTERIAL DNA; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; IN VITRO STUDY; INHIBITION ZONE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; CHEMISTRY; COMPARATIVE STUDY; DNA SEQUENCE; DRUG EFFECTS; ENTEROBACTERIACEAE; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; POLYMERASE CHAIN REACTION;

BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; DNA, BACTERIAL; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84947867553     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2498-3     Document Type: Article

References (65)

1. Lee CS, Doi Y (2014) Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother 46(3):149–164. doi:10.3947/ic.2014.46.3.149
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1–12. doi:10.1086/595011
3. Shiber S, Yahav D, Avni T, Leibovici L, Paul M (2014) Beta-Lactam/beta-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 70(1):41–47. doi:10.1093/jac/dku351
4. Ambler RP (1980) The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 289(1036):321–331
5. Queenan AM, Bush K (2007) Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20(3):440–458. doi:10.1128/CMR.00001-07
6. Goessens WH, van der Bij AK, van Boxtel R, Pitout JD, van Ulsen P, Melles DC, Tommassen J (2013) Antibiotic trapping by plasmid-encoded CMY-2 beta-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli. Antimicrob Agents Chemother 57(8):3941–3949. doi:10.1128/AAC.02459-12
7. Lavigne JP, Sotto A, Nicolas-Chanoine MH, Bouziges N, Bourg G, Davin-Regli A, Pages JM (2012) Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in Enterobacter aerogenes clinical isolates. Clin Microbiol Infect 18(6):539–545. doi:10.1111/j.1469-0691.2011.03607.x
8. Mallea M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, Bollet C, Pages JM (1998) Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 144(Pt 11):3003–3009
9. Livermore DM, Tulkens PM (2009) Temocillin revived. J Antimicrob Chemother 63(2):243–245. doi:10.1093/jac/dkn511
10. van der Waaij D (1985) Selective decontamination of the digestive tract with oral aztreonam and temocillin. Rev Infect Dis 7(Suppl 4):S628–S634
11. Woodford N, Pike R, Meunier D, Loy R, Hill R, Hopkins KL (2014) In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother 69(2):564–567. doi:10.1093/jac/dkt383
12. van Dijk K, Voets GM, Scharringa J, Voskuil S, Fluit AC, Rottier WC, Leverstein-Van Hall MA, Cohen Stuart JW (2014) A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and temocillin. Clin Microbiol Infect 20(4):345–349. doi:10.1111/1469-0691.12322
13. Huang TD, Poirel L, Bogaerts P, Berhin C, Nordmann P, Glupczynski Y (2014) Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers. J Antimicrob Chemother 69(2):445–450. doi:10.1093/jac/dkt367
14. Dewar S, Reed LC, Koerner RJ (2014) Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother 69(2):303–308. doi:10.1093/jac/dkt368
15. Sougakoff W, Jarlier VV (2000) Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases. J Antimicrob Chemother 46 [Suppl A]:9–14
16. Graninger W (2003) Pivmecillinam—therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 22 [Suppl 2]:73–78
17. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52(5):e103–e120. doi:10.1093/cid/ciq257
18. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL (2012) Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A 109(29):11663–11668. doi:10.1073/pnas.1205073109
19. Coleman K (2011) Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-lactamase inhibitors. Curr Opin Microbiol 14(5):550–555. doi:10.1016/j.mib.2011.07.026
20. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, Black MT (2009) In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 64(2):326–329. doi:10.1093/jac/dkp197
21. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N (2011) Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55(1):390–394. doi:10.1128/AAC.00756-10
22. Lagace-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG (2011) Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 55(5):2434–2437. doi:10.1128/AAC.01722-10
23. Guillon H, Tande D, Mammeri H (2011) Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum beta-lactamase AmpC. Antimicrob Agents Chemother 55(9):4443–4446. doi:10.1128/AAC.01513-10
24. CLSI (2010) Performance standards for antimicrobial susceptibility testing: 20th informational supplement M100-S20. Wayne, PA, USA
25. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL (2005) Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 43(7):3129–3135. doi:10.1128/JCM.43.7.3129-3135.2005
26. Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A (2009) Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J Clin Microbiol 47(6):1631–1639. doi:10.1128/JCM.00130-09
27. Giske CG, Gezelius L, Samuelsen O, Warner M, Sundsfjord A, Woodford N (2011) A sensitive and specific phenotypic assay for detection of metallo-beta-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin Microbiol Infect 17(4):552–556. doi:10.1111/j.1469-0691.2010.03294.x
28. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC (2001) Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45(4):1151–1161. doi:10.1128/AAC.45.4.1151-1161.2001
29. Poirel L, Heritier C, Tolun V, Nordmann P (2004) Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48(1):15–22
30. Kaase M, Szabados F, Pfennigwerth N, Anders A, Geis G, Pranada AB, Rossler S, Lang U, Gatermann SG (2014) Description of the metallo-beta-lactamase GIM-1 in Acinetobacter pittii. J Antimicrob Chemother 69(1):81–84. doi:10.1093/jac/dkt325
31. Marchiaro P, Mussi MA, Ballerini V, Pasteran F, Viale AM, Vila AJ, Limansky AS (2005) Sensitive EDTA-based microbiological assays for detection of metallo-{beta}-lactamases in nonfermentative gram-negative bacteria. J Clin Microbiol 43(11):5648–5652. doi:10.1128/JCM.43.11.5648-5652.2005
32. Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N (2006) Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 57(5):1012–1014. doi:10.1093/jac/dkl043
33. Rodriguez-Villalobos H, Malaviolle V, Frankard J, de Mendonca R, Nonhoff C, Struelens MJ (2006) In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 57(4):771–774. doi:10.1093/jac/dkl046
34. Adams-Haduch JM, Potoski BA, Sidjabat HE, Paterson DL, Doi Y (2009) Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 53(6):2700–2701. doi:10.1128/AAC.00290-09
35. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N (2011) What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 37(5):415–419. doi:10.1016/j.ijantimicag.2011.01.012
36. Vanstone GL, Dilley R, Schwenk S, Williams A, Balakrishnan I (2013) Temocillin disc diffusion susceptibility testing by EUCAST methodology. J Antimicrob Chemother 68(11):2688–2689. doi:10.1093/jac/dkt248
37. Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, Brudney D, Ladenheim D, Ghazy A, Khan I, Virgincar N, Iyer S, Carryn S, Van de Velde S (2011) Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 66(11):2628–2631. doi:10.1093/jac/dkr317
38. Gupta ND, Smith RE, Balakrishnan I (2009) Clinical efficacy of temocillin. J Antimicrob Chemother 64(2):431–433. doi:10.1093/jac/dkp208
39. Barton E, Flanagan P, Hill S (2008) Spinal infection caused by ESBL-producing Klebsiella pneumoniae treated with temocillin. J Infect 57(4):347–349. doi:10.1016/j.jinf.2008.08.001
40. Duerinckx JF (2008) Case report: subacute synovitis of the knee after a rose thorn injury: unusual clinical picture. Clin Orthop Relat Res 466(12):3138–3142. doi:10.1007/s11999-008-0482-2
41. Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D (2006) Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 57(2):367–368. doi:10.1093/jac/dki451
42. Titelman E, Iversen A, Kalin M, Giske CG (2012) Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 18(2):189–192. doi:10.1089/mdr.2011.0161
43. Wootton M, Walsh TR, Macfarlane L, Howe RA (2010) Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 65(1):79–81. doi:10.1093/jac/dkp404
44. Tarnberg M, Ostholm-Balkhed A, Monstein HJ, Hallgren A, Hanberger H, Nilsson LE (2011) In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 30(8):981–987. doi:10.1007/s10096-011-1183-4
45. Auer S, Wojna A, Hell M (2010) Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 54(9):4006–4008. doi:10.1128/AAC.01760-09
46. Brenwald NP, Andrews J, Fraise AP (2006) Activity of mecillinam against AmpC beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 58(1):223–224. doi:10.1093/jac/dkl198
47. Marrs EC, Day KM, Perry JD (2014) In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase. J Antimicrob Chemother 69(10):2873–2875. doi:10.1093/jac/dku204
48. Kahlmeter G, Poulsen HO (2012) Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 39(1):45–51. doi:10.1016/j.ijantimicag.2011.09.013
49. Nicolle LE, Mulvey MR (2007) Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis 39(8):748–749. doi:10.1080/00365540701367801
50. Søraas A, Sundsfjord A, Jorgensen SB, Liestol K, Jenum PA (2014) High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS One 9(1):e85889. doi:10.1371/journal.pone.0085889
51. Jansaker F, Frimodt-Moller N, Sjogren I, Dahl Knudsen J (2014) Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother 69(3):769–772. doi:10.1093/jac/dkt404
52. Craig WA (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17(3):479–501
53. Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou H, Souli M (2012) Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 67(10):2424–2428. doi:10.1093/jac/dks215
54. Lahiri SD, Giacobbe RA, Johnstone MR, Alm RA (2014) Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C beta-lactamase enzyme. J Antimicrob Chemother 69(11):2942–2946. doi:10.1093/jac/dku237
55. Levasseur P, Girard AM, Lavallade L, Miossec C, Pace J, Coleman K (2014) Efficacy of a ceftazidime-avibactam combination in a murine septicemia model caused by Enterobacteriaceae species producing AmpC or extended-spectrum beta-lactamases. Antimicrob Agents Chemother 58(11):6490–6495. doi:10.1128/AAC.03579-14
56. Flamm RK, Sader HS, Farrell DJ, Jones RN (2014) Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 80(3):233–238. doi:10.1016/j.diagmicrobio.2014.07.005
57. Flamm RK, Farrell DJ, Sader HS, Jones RN (2014) Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother 69(6):1589–1598. doi:10.1093/jac/dku025
58. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N (2012) Characterization of beta-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother 67(6):1354–1358. doi:10.1093/jac/dks079
59. Porres-Osante N, Dupont H, Torres C, Ammenouche N, de Champs C, Mammeri H (2014) Avibactam activity against extended-spectrum AmpC beta-lactamases. J Antimicrob Chemother 69(6):1715–1716. doi:10.1093/jac/dku002
60. Nordmann P, Mammeri H (2007) Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol 2(3):297–307. doi:10.2217/17460913.2.3.297
61. Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, Sable C (2012) Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28(12):1921–1931. doi:10.1185/03007995.2012.748653
62. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C (2013) Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68(5):1183–1192. doi:10.1093/jac/dks523
63. Robert-Koch-Institut (2013) Zur aktuellen Situation bei carbapenemase-bildenden gramnegativen Bakterien. Epid Bull 19/2013
64. Nordmann P, Poirel L, Dortet L (2012) Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 18(9):1503–1507. doi:10.3201/eid1809.120355
65. Pires J, Novais A, Peixe L (2013) Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. J Clin Microbiol 51(12):4281–4283. doi:10.1128/JCM.01634-13